News World Center

Biosimilar Market Worth Around 34865 Million USD by 2024 | Lucrative CAGR 32.6% In Global Market

Press release   •   Apr 25, 2019 08:06 EDT

Global Biosimilar Market is expected to grow significantly from USD 3,748 million in 2017 to USD 34,865 million in 2024, at a lucrative CAGR of 32.6% from 2018 to 2024.

The growth in the market is attributed to the growing demand of biosimilars for the treatment of various diseases such as cancer, rheumatoid, crohn’s disease, and psoriatic arthritis, among others. Moreover, increasing investment in research and development activities coupled with favorable policies to accelerate approvals of biosimilar drugs and lower cost of the biosimilar products are also boosting the market growth.

The years used for the assessment are as follows;

Historical year: 2014, 2015, and 2016

Base year: 2017

Forecast period: 2018 – 2024

Download Sample Copy Of This Report From Here: http://www.amecoresearch.com/sample/12153

RESEARCH METHODOLOGY

The research and analysis is based on the data and information obtained from various primary and secondary sources. The data obtained is validated by interacting with the companies of the concerned domain. The steps involved in the research methodology are;

Obtaining historical data of the market based on news, articles, publications, annual reports, white papers, surveys, and other secondary sources
Interacting with key opinion leaders of the market and developing data points based on interaction with them
Study of past trends in the market and their year on year Impact on the market size and share
Analyzing the collected data points
Bridging the data points to calculate the total biosimilar market and its various segments
Anticipating potential risks
Analyzing market forces such as drivers, restraints, and opportunities to assess new growth areas for the global biosimilar market
Finalizing the overall size and share of the global biosimilar market

OBJECTIVES:

To analyze market trends, opportunities, drivers, and restraints associated with the global biosimilar market
To study market response with respect to the mergers and acquisitions in the industry
To profile key companies operating in the biosimilar market and provide their competitive landscape

View Detail Report With Complete Table of Content@ http://www.amecoresearch.com/market-report/global-biosimilar-market-emr-12153

MARKET SCOPE

The research scope for biosimilar market is as follows:

By Products

Recombinant Nonglycosylated Protein
Insulin
Recombinant Human Growth Hormone (rHGH)
Granulocyte Colony Stimulating factor
Interferon
Recombinant Glycosylated Proteins
Erythropoietin
Monoclonal Antibodies
Adalimumab
Infliximab
Rituximab
Trastuzumab
Bevacizumab
Other Monoclonal Antibodies
Follitropin
Recombinant Peptides
Glucagon
Calcitonin

By Manufacturing Type

Contract Manufacturing
In-House Manufacturing

By Application

Oncology
Growth Hormone Deficiency
Autoimmune Diseases
Infectious Diseases
Blood Disorders
Chronic Diseases
Other Diseases

By Region

North America
Europe
Asia-Pacific
Rest of the World (RoW)

FREE ANALYSIS

Biosimilar products are safe and effective for the treatment of various diseases such as rheumatoid arthritis, cancer, and other complex diseases. Increasing product approvals and growing awareness regarding the use of biosimilar products are providing lucrative opportunities for the investors and major healthcare players to invest in the market. Owing to the increasing demand of biosimilars due to the low cost of treatment and their ability to treat various diseases, biosimilar products are expected to account for 30% of novel drug products launched during 2016-2020.

The growth in the biosimilar market is attributed to the growing demand of biosimilars for the treatment of various diseases such as cancer, rheumatoid, crohn’s disease, and psoriatic arthritis, among others. Moreover, increasing investment in research and development activities coupled with favorable policies to accelerate approvals of biosimilar drugs and lower cost of the biosimilar products are also boosting the market growth.

Geographically, Europe held the largest share of the market in 2017. The growth in the region is attributed to the growing prevalence of chronic diseases and increasing research and development activities in biosimilar products. Moreover, strong government support for the approval of biosimilar products as well as increasing investments is also driving the market growth in the region. Furthermore, growing awareness among people and presence of major biotechnology players in the region is also expected to augment the market growth. Asia-Pacific is expected to witness the highest CAGR during the forecast period owing to large old age population and rapid development of biotechnology sector in the region.

Some of the key companies operating in the market include Sandoz International GmbH, Teva Pharmaceutical Industries Ltd., Pfizer Inc., Amgen Inc, STADA Arzneimittel AG, Mylan N.V., Biocon, Samsung Bioepis, Dr. Reddy s Reddy’s Laboratories, Intas Biopharmaceuticals Ltd., Biocad, Amega Biotech, Qilu Pharmaceutical Co., Ltd, Prestige BioPharma Pte Ltd., Shanghai Fosun Pharmaceutical Group Co., Ltd., Celltrion Inc., among others.

Table of Contents

Global Biosimilar Market Outlook, Trend and Opportunity Analysis, Competitive Insights, Actionable Segmentation & Forecast 2024

CHAPTER 1. Market Scope and Methodology

1.1. Research methodology

1.2. Research scope & assumptions

1.3. List of data sources

CHAPTER 2. Executive Summary

2.1. Global Biosimilar- Market Snapshot

CHAPTER 3. Industry Analysis

3.1. Market definition

3.2. Market segmentation

3.3. Key findings of the global biosimilar market

3.4. Value chain analysis

3.5. Regulatory Overview

3.6. Market opportunities & trends

3.6.1. Increasing demand for biosimilars in emerging economics

3.7. Market dynamics

3.7.1. Market driver analysis

3.7.1.1. Growing demand for biosimilars for the treatment of various diseases

3.7.1.2. Favorable policies to accelerate approvals of biosimilar drugs

3.7.1.3. Lower cost of biosimilar products

3.7.1.4. Increasing investments in research and development activities

3.7.2. Market restraint analysis

3.7.2.1. Uncertain regulatory environment

3.7.2.2. Complexities in manufacturing

3.7.3. Industry Analysis-Porters five forces of analysis

CHAPTER 4. Competitive Outlook

4.1. Competitive analysis

4.2. Competitive factors

4.3. Company market share analysis

4.4. Strategies adopted

CHAPTER 5. Global Biosimilar Market Size and Forecast (2014 – 2024)

5.1. Global Biosimilar Market, By Products (USD Million)

5.1.1. Recombinant Nonglycosylated Protein

5.1.1.1. Insulin

5.1.1.2. Recombinant Human Growth Hormone (rHGH)

5.1.1.3. Granulocyte Colony Stimulating factor

5.1.1.4. Interferon

5.1.2. Recombinant Glycosylated Proteins

5.1.2.1. Erythropoietin

5.1.2.2. Monoclonal Antibodies

5.1.2.2.1. Adalimumab

5.1.2.2.2. Infliximab

5.1.2.2.3. Rituximab

5.1.2.2.4. Trastuzumab

5.1.2.2.5. Bevacizumab

5.1.2.2.6. Other Monoclonal Antibodies

5.1.2.3. Follitropin

5.1.3. Recombinant Peptides

5.1.3.1. Glucagon

5.1.3.2. Calcitonin

5.2. Global Biosimilar Market, By Manufacturing Type (USD Million)

5.2.1. Contract Manufacturing

5.2.2. In-House Manufacturing

5.3. Global Biosimilar Market, By Application (USD Million)

5.3.1. Oncology

5.3.2. Growth Hormone Deficiency

5.3.3. Autoimmune Diseases

5.3.4. Infectious Diseases

5.3.5. Blood Disorders

5.3.6. Chronic Diseases

5.3.7. Other Diseases

CHAPTER 6. Global Biosimilar Market Size and Forecast, By Geography (2014-2024)

6.1. North America Biosimilar Market

6.1.1. North America Biosimilar Market, By Products (USD Million)

6.1.2. North America Biosimilar Market, By Manufacturing Type (USD Million)

6.1.3. North America Biosimilar Market, By Application (USD Million)

6.1.4. North America Biosimilar Market, By Country (USD Million)

6.1.4.1. US

6.1.4.2. Canada

6.2. Europe Biosimilar Market

6.2.1. Europe Biosimilar Market, By Products (USD Million)

6.2.2. Europe Biosimilar Market, By Manufacturing Type (USD Million)

6.2.3. Europe Biosimilar Market, By Application (USD Million)

6.2.4. Europe Tube Market, By Country (USD Million)

6.2.4.1. Spain

6.2.4.2. Italy

6.2.4.3. Germany

6.2.4.4. France

6.2.4.5. U.K.

6.2.4.6. Russia

6.2.4.7. Rest of Europe

6.3. Asia-Pacific Biosimilar Market

6.3.1. Asia-Pacific Biosimilar Market, By Products (USD Million)

6.3.2. Asia-Pacific Biosimilar Market, By Manufacturing Type (USD Million)

6.3.3. Asia-Pacific Biosimilar Market, By Application (USD Million)

6.3.4. Asia-Pacific Biosimilar Market, By Country (USD Million)

6.3.4.1. Japan

6.3.4.2. China

6.3.4.3. India

6.3.4.4. South Korea

6.3.4.5. Australia

6.3.4.6. Rest of Asia-Pacific

6.4. Rest of the World (RoW) Biosimilar Market

6.4.1. Rest of the World (RoW) Biosimilar Market, By Products (USD Million)

6.4.2. Rest of the World (RoW) Biosimilar Market, By Manufacturing Type (USD Million)

6.4.3. Rest of the World (RoW) Biosimilar Market, By Application (USD Million)

6.4.4. Rest of the World (ROW) Biosimilar Market, By Country (USD Million)

6.4.4.1. Brazil

6.4.4.2. Rest of the World

CHAPTER 7. Key Players and Strategic Developments

7.1. Sandoz International GmbH

7.1.1. Business Overview

7.1.2. Product and Service Offering

7.1.3. Financial Overview

7.1.4. Strategic Developments

7.2. Teva Pharmaceutical Industries Ltd.

7.2.1. Business Overview

7.2.2. Product and Service Offering

7.2.3. Financial Overview

7.2.4. Strategic Developments

7.3. Pfizer Inc.

7.3.1. Business Overview

7.3.2. Product and Service Offering

7.3.3. Financial Overview

7.3.4. Strategic Developments

7.4. Amgen Inc

7.4.1. Business Overview

7.4.2. Product and Service Offering

7.4.3. Financial Overview

7.4.4. Strategic Developments

7.5. STADA Arzneimittel AG

7.5.1. Business Overview

7.5.2. Product and Service Offering

7.5.3. Financial Overview

7.5.4. Strategic Developments

7.6. Mylan N.V.

7.6.1. Business Overview

7.6.2. Product and Service Offering

7.6.3. Financial Overview

7.6.4. Strategic Developments

7.7. Biocon

7.7.1. Business Overview

7.7.2. Product and Service Offering

7.7.3. Financial Overview

7.7.4. Strategic Developments

7.8. Samsung Bioepis

7.8.1. Business Overview

7.8.2. Product and Service Offering

7.8.3. Financial Overview

7.8.4. Strategic Developments

7.9. Dr. Reddy s Reddy’s Laboratories

7.9.1. Business Overview

7.9.2. Product and Service Offering

7.9.3. Financial Overview

7.9.4. Strategic Developments

7.10. Intas Biopharmaceuticals Ltd.

7.10.1. Business Overview

7.10.2. Product and Service Offering

7.10.3. Financial Overview

7.10.4. Strategic Developments

7.11. Biocad

7.11.1. Business Overview

7.11.2. Product and Service Offering

7.11.3. Financial Overview

7.11.4. Strategic Developments

7.12. Amega Biotech

7.12.1. Business Overview

7.12.2. Product and Service Offering

7.12.3. Financial Overview

7.12.4. Strategic Developments

7.13. Qilu Pharmaceutical Co., Ltd

7.13.1. Business Overview

7.13.2. Product and Service Offering

7.13.3. Financial Overview

7.13.4. Strategic Developments

7.14. Prestige BioPharma Pte Ltd.

7.14.1. Business Overview

7.14.2. Product and Service Offering

7.14.3. Financial Overview

7.14.4. Strategic Developments

7.15. Shanghai Fosun Pharmaceutical(Group)Co., Ltd.

7.15.1. Business Overview

7.15.2. Product and Service Offering

7.15.3. Financial Overview

7.15.4. Strategic Developments

7.16. Celltrion Inc.

7.16.1. Business Overview

7.16.2. Product and Service Offering

7.16.3. Financial Overview

7.16.4. Strategic Developments

Quick Buy This Premium Report From Here: http://www.amecoresearch.com/buy/12153

About Us:

Ameco Research is the one spot destination for all your research needs. Ameco Research holds the repository of quality research reports from numerous publishers across the globe. Our inventory of research reports caters to various industry verticals including Healthcare, Information and Communication Technology (ICT), Technology and Media, Chemicals, Materials, Energy, Heavy Industry, etc. With the complete information about the publishers and the industries they cater to for developing market research reports, we help our clients in making purchase decision by understanding their requirements and suggesting best possible collection matching their needs.

Contact:
Email: sales@amecoresearch.com | + 1 407 915 4157

Browse More For Latest Update :

Ameco Research